Tonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit
2024年8月13日 - 9:00PM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a fully-integrated biopharmaceutical company with
marketed products and a pipeline of development candidates,
announced today that Seth Lederman, M.D., President and Chief
Executive Officer of Tonix Pharmaceuticals, will present at the
Summer 2024 Virtual Investor Summit on Tuesday, August 20, 2024, at
11:00 a.m. ET.
Investors interested in arranging a meeting with
the Company’s management virtually during the conference should
contact the Investor Summit conference coordinator. A webcast of
the presentation will be available under the IR Events tab of the
Tonix website at www.tonixpharma.com.
Tonix Pharmaceuticals Holding
Corp.*Tonix is a fully-integrated
biopharmaceutical company focused on developing, licensing and
commercializing therapeutics to treat and prevent human disease and
alleviate suffering. Tonix’s development portfolio is focused on
central nervous system (CNS) disorders. Tonix’s priority is to
submit a New Drug Application (NDA) to the FDA in the second half
of 2024 for TNX-102 SL, a product candidate for which two
statistically significant Phase 3 studies have been completed for
the management of fibromyalgia. The FDA has granted Fast Track
designation to TNX-102 SL for the management of fibromyalgia.
TNX-102 SL is also being developed to treat acute stress reaction.
Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a
biologic designed to treat cocaine intoxication that has
Breakthrough Therapy designation. Tonix’s immunology development
portfolio consists of biologics to address organ transplant
rejection, autoimmunity and cancer, including TNX-1500, which is a
humanized monoclonal antibody targeting CD40-ligand (CD40L or
CD154) being developed for the prevention of allograft rejection
and for the treatment of autoimmune diseases. Tonix also has
product candidates in development in the areas of rare disease and
infectious disease. Tonix Medicines, our commercial subsidiary,
markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and
Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute
migraine with or without aura in adults.
*Tonix’s product development candidates are
investigational new drugs or biologics and have not been approved
for any indication.
Zembrace SymTouch and Tosymra are registered
trademarks of Tonix Medicines. All other marks are property of
their respective owners.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking
StatementsCertain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, risks
related to the failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations; risks related to the failure to
successfully market any of our products; risks related to the
timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any pharmaceutical under development, there
are significant risks in the development, regulatory approval and
commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2023, as filed
with the Securities and Exchange Commission (the “SEC”) on April 1,
2024, and periodic reports filed with the SEC on or after the date
thereof. All of Tonix's forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements.
The information set forth herein speaks only as of the date
thereof.
Investor Contact
Jessica MorrisTonix
Pharmaceuticalsinvestor.relations@tonixpharma.com (862)
904-8182
Peter VozzoICR
Westwickepeter.vozzo@westwicke.com (443) 213-0505
Media Contact
Katie
DodgeLaVoieHealthSciencekdodge@lavoiehealthscience.com(978)
360-3151
Tonix Pharmaceuticals (NASDAQ:TNXP)
過去 株価チャート
から 8 2024 まで 9 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
過去 株価チャート
から 9 2023 まで 9 2024